)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
PureTech Health (PRTC) investor relations material
PureTech Health H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary28 Aug, 2025
Executive summary
Entered 2025 with strong clinical and financial momentum, advancing late-stage programs and launching new entities including Seaport Therapeutics, Gallup Oncology, Silea (Celea) Therapeutics, and progressing key assets.
Maintained a hub-and-spoke model for early-stage asset development, efficient capital allocation, and risk mitigation.
Strong financial position with $319.6M in cash as of June 30, 2025, providing operational runway into 2028.
Management changes included interim CEO and chair appointments, with plans to add UK capital markets expertise to the board.
Significant value expected from royalties and milestones, including Cabenci and Cobenfy (KarXT), with modeled value around $300M over time.
Financial highlights
Ended H1 2025 with just under $320M in cash, cash equivalents, and short-term investments, down from $366M at FY 2024.
Total revenue for H1 2025 was $1.9M, up 542% year-over-year, driven by royalty revenue; grant revenue decreased.
Operating expenses for H1 2025 were just under $50M, down from $66.7M in H1 2024, reflecting spinouts, cost discipline, and workforce reductions.
R&D and G&A expenses expected to decrease further as Gallup and Silea (Celea) spin out.
Net loss attributable to owners was $44.6M, compared to $41.8M in H1 2024.
Outlook and guidance
Focused on securing external funding for Gallup and Silea (Celea), which will further extend cash runway and reduce direct R&D spend.
Phase III trial for Silea/Celea's lead program (deupirfenidone) in IPF expected to initiate in 2026, pending FDA alignment.
Key data readouts for Gallup Oncology's LYT200 expected in 2025 and 2026.
Vedanta’s VE303 Phase 3 topline data expected in 2026; Seaport’s Phase 2b BUOY-1 study ongoing.
What makes LYT-100 differentiated in IPF?
How does Seaport's Glyph platform work?
What is the key driver for Cobenfy sales upside?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next PureTech Health earnings date
H2 202529 Apr, 2026
Next PureTech Health earnings date
H2 202529 Apr, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
PureTech Health is an American clinical-stage biotherapeutics company that works with the discovery, development, and commercialization of medicines. PureTech’s pipeline includes proprietary product candidates in Phase 2 and Phase 3 clinical development that address significant unmet needs in oncology, central nervous system disorders, inflammatory disease, and gastrointestinal diseases. PureTech has a portfolio of proprietary, investigational medicines that are being developed with leading academic institutions as well as under strategic partnerships with other pharmaceutical companies.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage